Table 1.
Patient demographics and clinical features at the time of MPN-AP/BP diagnosis
| Variable |
IDH1/2-mutated n = 35 |
IDH1/2wt n = 131 |
P value |
|---|---|---|---|
| Patient demographics and laboratory data | |||
| Age at diagnosis, median (IQR) | 69.5 (14.1) | 67.8 (12.4) | .57∗ |
| White blood count, median (IQR), ×103/μL | 11.4 (18.3) | 8.7 (25.2) | .32∗ |
| Platelet count, median (IQR), ×103/μL | 72.0 (159.0) | 110.0 (51.0, 162.0) | .10∗ |
| Hemoglobin, median (IQR), g/dL | 8.3 (2.2) | 8.5 (2.2) | .59∗ |
| Peripheral blast, median (IQR), % | 21.0 (25.0) | 10.0 (20.0) | .0001∗ |
| Marrow blast, median (IQR), % | 22.8 (37.5) | 22.0 (25.0) | .57∗ |
| Total bilirubin, median (IQR), g/dL | 0.7 (0.3) | 0.7 (0.6) | .27∗ |
| Creatinine, median (IQR), g/dL | 0.9 (0.5) | 1.0 (0.5) | .53∗ |
| Palpable splenomegaly, n (%) | 14 (41.2) | 69 (53.9) | .19∗∗ |
| Chronic-phase MPN type, n (%) | .28∗∗ | ||
| Polycythemia vera | 7 (20.0) | 25 (19.1) | |
| Essential thrombocythemia | 9 (25.7) | 37 (28.2) | |
| Primary myelofibrosis | 9 (25.7) | 49 (37.4) | |
| Other MPN | 10 (28.6) | 20 (15.3) | |
| MPN driver mutation, n (%) | |||
| JAK2 | 26 (74.3) | 78 (59.5) | .11∗∗ |
| CALR | 3 (8.6) | 25 (19.1) | .20∗∗∗ |
| MPL | 3 (8.6) | 13 (9.9) | 1.00∗∗∗ |
| Triple negative | 4 (11.4) | 17 (13.0) | 1.00∗∗∗ |
| ELN22 adverse-risk mutations, n (%) | |||
| ASXL1 | 13 (37.1) | 39 (29.8) | .40∗∗ |
| EZH2 | 4 (11.4) | 11 (8.4) | .52∗∗∗ |
| SRSF2 | 15 (42.9) | 24 (18.3) | .002∗∗ |
| STAG2 | 2 (5.7) | 5 (3.8) | .64∗∗∗ |
| TP53 | 6 (17.1) | 37 (28.2) | .18∗∗ |
| U2AF1 | 1 (2.9) | 11 (8.4) | .46∗∗∗ |
| BCOR | 0 (0.0) | 5 (3.8) | .59∗∗∗ |
| RUNX1 | 12 (34.3) | 17 (13.0) | .003∗∗ |
| SF3B1 | 2 (5.7) | 10 (7.6) | 1.00∗∗∗ |
| ZRSR2 | 1 (2.9) | 4 (3.1) | 1.00∗∗∗ |
ELN22, European LeukemiaNet 2022; IQR, interquartile range.
∗
Median test.
∗∗
χ2 test.
∗∗∗
Fisher exact test.